First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
After several discontinuations, a new ADC enters the clinic.
